Abalone Bio is a preclinical-stage biotechnology company headquartered in Emeryville, California, that develops therapeutic antibody drugs targeting GPCRs, ion channels, and other membrane proteins.
Subscribe to see Abalone Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Abalone Bio is a biotechnology company headquartered in United States. It has raised at least $150,000 across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Grant, closed in June 2020. Xcout tracks 9 named people at Abalone Bio, including Toshi Takeuchi (CSO).
3 more named people on record for Abalone Bio, with roles, board committees and tenure — see the full roster →
At least $150,000 raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Grant | Undisclosed | 1 named | |
| Seed | $150,000 | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Abalone Bio's closest competitors — see the full list of competitors and alternatives →
Prellis Biologics, Inc. is a privately held biotechnology company headquartered in Berkeley, California, within the San Francisco Bay Area. It develops human antibody therapeutics and focuses on antibody discovery leveraging AI and immune diversity.
Great Bay Bio is a biotech company headquartered in HKSTP that drives drug development using cutting-edge technologies such as AI and big data mining.
Standard Model Biomedicine is a biotechnology research company based in San Francisco, United States. The company is focused on developing a foundation model for human biology to advance biomedical research.
Archon Biosciences is a biotechnology company based in Seattle, Washington, supported by investors like Madrona Ventures. The company utilizes its proprietary AbC technology platform to develop innovative therapeutics and advance drug pipelines.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.